Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Neil Shah

20PUBLICATIONS

172CO-AUTHORS

Environmental epidemiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsImmunogenetics (incl. genetic immunology)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (20)

Sort by Publication Date:

|May 05, 2026

Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial.

|Nov 02, 2025

Associations Between Anxiety or Depression Diagnosis and Immune Checkpoint Inhibitor Outcomes.

Heather Derry-Vick, Neil J Shah, Jaeil Ahn

|Oct 13, 2025

Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes.

Neil J Shah, Reshma Shinde, Rituparna Bhattacharya

|Aug 29, 2025

Pragmatic Use of Minimal Common Oncology Data Elements and Observational Medical Outcomes Partnership at an Academic Medical Center.

Tatyana Sandler, Sarah Manglicmot, Katelyn M Mullen

|Jun 23, 2025

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.

Kathryn E Beckermann, Neil J Shah, Matthew T Campbell

|May 14, 2025

Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies.

Neil J Shah, Sneha Sura, Reshma Shinde

Pageof 4

Frequent Collaborators

4 joint publications

Robert J Motzer

4 joint publications

Maria Isabel Carlo

4 joint publications

Ritesh R Kotecha

3 joint publications

Michael B Atkins

3 joint publications

Chung-Han Lee

3 joint publications

Martin H Voss

3 joint publications

Darren R Feldman

3 joint publications

Andrea Knezevic

3 joint publications

David M Faleck

2 joint publications

Arnold L Potosky

Frequent Collaborators

4 joint publications

Robert J Motzer

4 joint publications

Maria Isabel Carlo

4 joint publications

Ritesh R Kotecha

3 joint publications

Michael B Atkins

Top Related Videos

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on : Aug 19, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on : Feb 05, 2020

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on : Apr 12, 2017

See more related videos

Top Related Videos

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on : Aug 19, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on : Feb 05, 2020

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on : Apr 12, 2017

See more related videos